Cargando…
Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765758/ https://www.ncbi.nlm.nih.gov/pubmed/35072108 http://dx.doi.org/10.1016/S2665-9913(21)00417-3 |
| _version_ | 1784634381608943616 |
|---|---|
| author | Frey, Sarah Chiang, Teresa Po-Yu Connolly, Caoilfhionn M Teles, Mayan Alejo, Jennifer L Boyarsky, Brian J Christopher-Stine, Lisa Werbel, William A Massie, Allan B Segev, Dorry L Paik, Julie J |
| author_facet | Frey, Sarah Chiang, Teresa Po-Yu Connolly, Caoilfhionn M Teles, Mayan Alejo, Jennifer L Boyarsky, Brian J Christopher-Stine, Lisa Werbel, William A Massie, Allan B Segev, Dorry L Paik, Julie J |
| author_sort | Frey, Sarah |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8765758 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-87657582022-01-19 Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease Frey, Sarah Chiang, Teresa Po-Yu Connolly, Caoilfhionn M Teles, Mayan Alejo, Jennifer L Boyarsky, Brian J Christopher-Stine, Lisa Werbel, William A Massie, Allan B Segev, Dorry L Paik, Julie J Lancet Rheumatol Comment Elsevier Ltd. 2022-04 2022-01-18 /pmc/articles/PMC8765758/ /pubmed/35072108 http://dx.doi.org/10.1016/S2665-9913(21)00417-3 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Comment Frey, Sarah Chiang, Teresa Po-Yu Connolly, Caoilfhionn M Teles, Mayan Alejo, Jennifer L Boyarsky, Brian J Christopher-Stine, Lisa Werbel, William A Massie, Allan B Segev, Dorry L Paik, Julie J Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease |
| title | Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease |
| title_full | Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease |
| title_fullStr | Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease |
| title_full_unstemmed | Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease |
| title_short | Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease |
| title_sort | antibody durability 6 months after two doses of sars-cov-2 mrna vaccines in patients with rheumatic and musculoskeletal disease |
| topic | Comment |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765758/ https://www.ncbi.nlm.nih.gov/pubmed/35072108 http://dx.doi.org/10.1016/S2665-9913(21)00417-3 |
| work_keys_str_mv | AT freysarah antibodydurability6monthsaftertwodosesofsarscov2mrnavaccinesinpatientswithrheumaticandmusculoskeletaldisease AT chiangteresapoyu antibodydurability6monthsaftertwodosesofsarscov2mrnavaccinesinpatientswithrheumaticandmusculoskeletaldisease AT connollycaoilfhionnm antibodydurability6monthsaftertwodosesofsarscov2mrnavaccinesinpatientswithrheumaticandmusculoskeletaldisease AT telesmayan antibodydurability6monthsaftertwodosesofsarscov2mrnavaccinesinpatientswithrheumaticandmusculoskeletaldisease AT alejojenniferl antibodydurability6monthsaftertwodosesofsarscov2mrnavaccinesinpatientswithrheumaticandmusculoskeletaldisease AT boyarskybrianj antibodydurability6monthsaftertwodosesofsarscov2mrnavaccinesinpatientswithrheumaticandmusculoskeletaldisease AT christopherstinelisa antibodydurability6monthsaftertwodosesofsarscov2mrnavaccinesinpatientswithrheumaticandmusculoskeletaldisease AT werbelwilliama antibodydurability6monthsaftertwodosesofsarscov2mrnavaccinesinpatientswithrheumaticandmusculoskeletaldisease AT massieallanb antibodydurability6monthsaftertwodosesofsarscov2mrnavaccinesinpatientswithrheumaticandmusculoskeletaldisease AT segevdorryl antibodydurability6monthsaftertwodosesofsarscov2mrnavaccinesinpatientswithrheumaticandmusculoskeletaldisease AT paikjuliej antibodydurability6monthsaftertwodosesofsarscov2mrnavaccinesinpatientswithrheumaticandmusculoskeletaldisease |